National Institute for Materials Science

Other

Japan Science and Technology Agency

Nof Corporation

Furuuchi Chemical Corporation

Tetsushi Taguchi

Junzo Tanaka

Akio Hayashi

Mitsuru Akashi

Akio Kishida

Yasuyuki Katada

Hirofumi Saito

Ryozo Nagai

Toshiyuki Ikoma

Katsuhito Fujiu

Makoto Sasaki

Hisatoshi Kobayashi

Miyuki Matsuda

Ichiro Manabe

Akihiro Nishiguchi

The present invention addresses the problem of providing a powder that has excellent adhesive strength to biological tissue when applied to a wound-covering material or the like. The present invention also addresses the problem of providing a wound-covering material and an adhesion prevention material. The powder contains particles containing a crosslinked gelatin derivative, wherein the gelatin derivative has a structure represented by formula (1): GltnNH-L-CHR1R2 (in the formula, Gltn represents a residue of gelatin, L represents a single bond or a divalent linking group, Rrepresents a hydrocarbon group having 1-20 carbon atoms, and Rrepresents a hydrogen atom or a hydrocarbon group having 1-20 carbon atoms), the particles have an average sphericity of 1.45 or less, and the standard deviation of the sphericity of the particles is 0.25 or less.

Powder, wound-covering material, adhesion prevention material, hemostatic material, and production method for powder

The present invention addresses the problem of providing an angiogenesis promoter capable of exerting an excellent angiogenesis promoting effect without containing any growth factor. The present invention also addresses the problem of providing a therapeutic method. An angiogenesis promoter that comprises as an active ingredient at least one member selected from the group consisting of a gelatin derivative represented by formula 1 and a crosslinked product of the gelatin derivative: In formula 1: Gltn represents a gelatin residue; L represents a single bond or a divalent linking group; and Rand Rindependently represent a hydrocarbon group having 1-20 carbon atoms or a hydrogen atom, provided that at least one of Rand Rrepresents the aforesaid hydrocarbon group.

Angiogenesis promoter and therapeutic method

A wound dressing material includes a particle having a crosslinked gelatin derivative, the gelatin derivative having the structure represented by the following formula (1):GltnNH—CHRR  (1)wherein 'Gltn' represents a gelatin residue, Rrepresents an alkyl group having 1-17 carbon atoms, and Rrepresents a hydrogen atom or an alkyl group having 1-17 carbon atoms, and the particle having a particle size ranging from 1 to 1,000 μm.

Wound dressing containing crosslinked gelatin derivative particles

A method of hemostasis includes the step of applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has (a) a weight average molecular weight of from 10,000 to 50,000, (b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and (c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and a second agent including a crosslinking agent for the gelatin derivative.

Method of hemostasis

A surgical sealant consisting of (1) a first agent comprising a gelatin derivative, wherein the gelatin derivative (a) has a weight average molecular weight of from 10,000 to 50,000; (b) has a hydrophobic group bonded thereto, the hydrophobic group being an alkyl group having 6 to 18 carbon atoms; (c) has a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and (d) comprises a structure represented by the following formula: GltnNH&#x2014;CHRR, wherein 'Gltn' represents a gelatin residue, Ris the hydrophobic group, and Ris a hydrogen atom or the hydrophobic group; and (2) a second agent comprising a crosslinking agent for the gelatin derivative.

Surgical sealant

A surgical sealant comprising a first agent containing a hydrophobically-modified gelatin derived from a cold-water fish, and a second agent containing a water-soluble molecule for crosslinking, wherein the water-soluble molecule for crosslinking is at least one kind selected from the group consisting of poly acids and acid anhydrides having two or more active ester groups, and aldehyde compounds having two or more aldehyde groups, the hydrophobically-modified gelatin derived from a cold-water fish is a gelatin in which at least a part of amino groups of side chains of a gelatin derived from a cold-water fish has been substituted by hydrophobic groups, and the hydrophobic groups are linear chain aliphatic groups each having 8 to 18 carbon atoms, with a substitution rate (number of moles of hydrophobic groups/(total number of moles of hydrophobic groups and reactive amino groups in gelatin)&#xd7;100) of 3 to 20 mol %.

There is provided a tissue adhesive to be applied to a tissue by mixing an adhesive component including an aqueous solution of a fish-derived gelatin with a curative component including an aqueous solution of a water-soluble crosslinking reagent, wherein the water-soluble crosslinking reagent has an amide linkage or an ethylene glycol unit or a sugar chain in the molecular main chain thereof and has two or more of an active ester group or an acid anhydride or an aldehyde group.

Tissue adhesive and method for producing same

The present invention addresses the problem of providing: a two-component tissue adhesive having high adhesive strength and high biocompatibility; and a method for producing the two-component tissue adhesive. The present invention involves a two-component tissue adhesive comprising hydrophobically-modified gelatin as a first agent and a cross-linking reagent as a second agent. The hydrophobically-modified gelatin is provided with an amino group and a hydrophobic group on the side chain thereof, and the cross-linking reagent has two or more active ester groups or anhydrides within a single molecule.

Two-component tissue adhesive and method for producing same

Provided is a bio-hybrid material that does not cause elution of nickel ions and has an excellent endothelialization ability, a production method therefor, and a stent. The bio-hybrid material () used includes an alloy part () free of Ni, an organic acid () having two or more active esters, and a cytokine (). The alloy part () free of Ni forms an ester bond with the organic acid (), and the organic acid () and the cytokine () are immobilized via an amide bond.

Bio-hybrid material, production method therefor, and stent

A nickel-free stainless steel stent using a stainless steel which does not substantially contain Ni in the stainless steel, has a metal allergy onset-preventing effect, and is excellent in terms of precision workability, strength, and ductility, is provided. The nickel-free stainless steel stent is characterized by using a stainless steel containing, as a chemical composition, from 15 to 30% by mass of Cr, from 0.97 to 2% by mass of Mo, and from 0.5 to 1% by mass of N, with the remainder being Fe, and optionally containing inevitable impurities.

Nickel-free stainless steel stent

This invention relates to a scaffold consisting of a biodegradable polymeric material with a composition gradient of calcium phosphate that is capable of effectively regenerating the hard/soft tissue interface and an implant for hard/soft tissue filling with the utilization of such scaffold.

Composite material containing a calcium phosphate gradient

The crosslinking agents and condensing agents that have been employed in biological adhesives and in treating medical devices such as cardiac valves are non-natural compounds synthesized artificially. Thus, they are not metabolized in vivo and exhibit toxicity to living bodies. These compounds are thus used only in a restricted amount and for limited purposes in the clinical sites. The present invention provides a biological low-molecular-weight derivative obtained by modifying carboxyl groups of a biological low-molecular-weight compound with N-hydroxysuccinimide, N-hydroxysulfosuccinimide, or a derivative thereof and a crosslinked high-molecular-weight product obtained by crosslinking various high-molecular-weight compounds with this derivative.

Biological low-molecular-weight derivatives

A porous and spherical calcium phosphate particle which is substituted with a metal ion or has a metal ion carried on the surface thereof, and has a particle diameter of 0.1 to 100 &#x3bc;m. The calcium phosphate particle is a novel functional particle which is useful, for example, as a material for use in gas chromatography allowing the separation of a chemical substance of a trace amount with high accuracy.

Porous and spherical calcium phosphate particle comprising metal ion, and porous multilayer calcium phophate particle

A hydroxyapatite consisting substantially of Ca (PO ) (OH) , and having a crystal structure which has at least two diffraction peaks at 31-32 degrees and 26 degrees in X-ray diffractometry; and a process for producing a hydroxyapatite which comprises the step (A) of immersing a substrate in a first aqueous solution containing calcium ions and a second solution containing PO ions to generate the hydroxyapatite at least on the surface of the substrate and the step (B) of recovering the hydroxyapatite from the substrate.

Hydroxyapatite, composite, processes for producing these, and use of these

A method for preparing a hydroxyapatite composite is disclosed. This method comprises alternately soaking a matrix which has been made hydrophilic at least on its surface, in a calcium ion aqueous solution containing calcium ions and substantially free of phosphate ions and in a phosphate ion aqueous solution containing phosphate ions and substantially free of calcium ions to securely form hydroxyapatite at least on the surface of the matrix. Also disclosed is a biocompatible material composed of the hydroxyapatite composite obtained by the method.

Growing community of inventors

Tsukuba, Japan

Tetsushi Taguchi